Prat et al.25 study showed that compared with HR-HER2+ breast cancer, the tpCR rate obtained by NACT combined with trastuzumab was relatively low in HR+HER2+ ones (35.6% versus 19%). This evidence concerns the gene ERBB2 and breast carcinoma.